BRUKER CORP's Annual Report: What Investors Need to Know

Business Overview

BRUKER CORP stands as a global powerhouse in high-performance scientific instruments and solutions, powering innovation across life sciences, materials research, and industrial applications. The company operates through key segments:

• BSI BioSpin: Focuses on nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) spectroscopy for life science research and drug discovery.
• CALID: Provides mass spectrometry and chromatography solutions for clinical, applied, and research markets.
• NANO: Offers atomic force microscopy and other nanoscale measurement tools.
• Energy & Supercon Technologies: Specializes in superconducting materials and devices.

Management Discussion (MD&A Highlights)

Last year, BRUKER CORP pursued a clear growth strategy, focusing on targeted acquisitions and operational optimization.

Strategic Growth & Key Developments

BRUKER CORP actively expanded its capabilities and market reach through strategic acquisitions:

• Novalix (2024): Enhanced drug discovery and development services.
• AST Revolution LLC (2025): Strengthened offerings in advanced materials and industrial applications.
• PreOmics (late 2025): Expanded proteomics solutions for life science research.
• Tofwerk AG (early 2026): Bolstered real-time gas and aerosol analysis capabilities, extending their mass spectrometry portfolio.

These acquisitions highlight the company's commitment to innovation and leadership in specialized, high-growth scientific instrumentation markets. BRUKER CORP also authorized a stock repurchase program in May 2023, signaling confidence in its valuation and its commitment to returning value to shareholders.

Operational Adjustments & Restructuring

BRUKER CORP undertook significant restructuring initiatives to enhance efficiency and optimize its global operations:

• BCA Restructuring Program (2024): Focused on specific adjustments within its Bruker Chemical and Applied Markets division.
• Corporate-Wide Restructuring Plan (2025): A broader initiative to streamline operations, reduce costs, and improve overall profitability.

These programs incurred associated costs, such as employee severance and inventory adjustments. The company strategically aims to position itself for greater long-term efficiency and sustained growth.

Financial Health

BRUKER CORP uses various financing methods, including Switzerland Francs Notes and Term Loan Agreements. It also employs hedging activities, such as cross-currency and interest rate swap agreements, to manage financial risks from currency fluctuations and interest rate changes.

Risk Factors

• Customer Concentration: BRUKER CORP reported a diversified customer base, with no single customer accounting for a significant portion of its sales revenue in 2025 or accounts receivable in 2024. This indicates reduced reliance on any one client.
• Product Concentration: The company identified a product concentration risk for 2025.

Future Outlook

The company's strategic acquisitions and restructuring efforts indicate a forward-looking strategy. This strategy focuses on continued innovation, operational excellence, and expansion into new applications within life sciences, advanced materials, and analytical instrumentation. It aims to strengthen market leadership and capitalize on growth opportunities in specialized scientific and technological fields.

Competitive Position

Operating in highly specialized and competitive markets, BRUKER CORP's consistent strategy of acquiring complementary technologies and companies – such as Novalix, AST Revolution, PreOmics, and Tofwerk AG – clearly indicates its proactive approach. This strategy strengthens its competitive position and expands its market share in high-growth scientific and technological fields. The company leverages its technological expertise and broad product portfolio to differentiate itself.